Silence Therapeutics plc (SLN) - Dilution Analysis

S-3 filing: The company is filing a shelf registration to offer up to $100,000,000 of American Depositary Shares (ADSs) in an at-the-market offering.

10-Q filing | 141.7M shares outstanding

10-Q filing | 141.7M shares outstanding

10-Q filing | 141.7M shares outstanding

10-K filing | 138.8M shares outstanding

F-3 filing: This F-3 filing relates to the resale of up to 5,714,286 American Depositary Shares, representing 17,142,858 ordinary shares, of Silence Therapeutics plc by selling securityholders.

20-F filing | 118.8M shares outstanding

20-F filing | 107.8M shares outstanding

20-F filing | 89.8M shares outstanding

POS AM filing: This is a post-effective amendment to a registration statement for a shelf offering of common stock.

F-3 filing: Silence Therapeutics PLC files an F-3 to offer and sell up to $300,000,000 of its ordinary shares from time to time.

POS AM filing: This is a POS AM filing detailing the expenses associated with the registration of ordinary shares, including SEC registration fees, Nasdaq listing fees, printing expenses, legal fees, accounting fees, and miscellaneous expenses, totaling $1,100,000.

POS AM filing: This prospectus relates to the resale from time to time in one or more offerings by the selling shareholders named herein of up to an aggregate of 6,066,654 of our ordinary shares, nominal value £0.05 per share, represented by 2,022,218 American Depositary Shares, or ADSs.

F-1 filing: F-1 filing for the resale of up to 6,066,654 ordinary shares by selling shareholders.

F-1 filing: Filing relates to the registration of 53,732,291 ordinary shares held by existing shareholders, which may be offered as American Depositary Shares (ADSs) on the Nasdaq Capital Market.